1. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review.
- Author
-
Chan, David, Chan, David, Bergsland, Emily, Chan, Jennifer, Gadgil, Rujuta, Halfdanarson, Thorvardur, Hornbacker, Kathleen, Kelly, Virginia, Kunz, Pamela, McGarrah, Patrick, Raj, Nitya, Reidy, Diane, Thawer, Alia, Whitman, Julia, Wu, Linda, Becker, Christoph, Singh, Simron, Chan, David, Chan, David, Bergsland, Emily, Chan, Jennifer, Gadgil, Rujuta, Halfdanarson, Thorvardur, Hornbacker, Kathleen, Kelly, Virginia, Kunz, Pamela, McGarrah, Patrick, Raj, Nitya, Reidy, Diane, Thawer, Alia, Whitman, Julia, Wu, Linda, Becker, Christoph, and Singh, Simron
- Abstract
BACKGROUND: Grade 3 gastroenteropancreatic neuroendocrine neoplasms (G3 GEPNENs) are often aggressive, and the optimal treatment is unclear for this subgroup of neuroendocrine neoplasms (NENs). Temozolomide (TEM)-based regimens have been increasingly used to treat grade 1-2 NENs, but their efficacy in G3 NENs remains undetermined. We aimed to assess the clinical efficacy of TEM-containing regimens in advanced grade 3 GEPNENs. MATERIALS AND METHODS: A multicenter retrospective review (2008-2018) of patients with metastatic/unresectable G3 GEPNENs who received a TEM-containing regimen was undertaken within a North American partnership to pool data. The primary endpoint was time to treatment failure (TTF). Radiologic response was extracted from local reports. RESULTS: One hundred and thirty patients in six high-volume NEN centers were included (median age 55, 64% male, 18% functional, 67% pancreatic NEN). Forty-nine percent were well-differentiated, 35% poorly differentiated, and 15% unknown based on local pathology reports. The regimen used was capecitabine and temozolomide (CAPTEM) in 92% and TEM alone in 8%. Radiological response by local assessment was seen in 36% of patients. Median TTF was 3.6 months and median overall survival (OS) 19.2 months. Six percent of patients required discontinuation of therapy due to adverse events. TTF was longer in first-line treatment (7.8 months vs. 2.9 months; hazard ratio, 1.62; 95% confidence interval, 1.11-2.36; p = .015) and in patients with pancreatic NENs (panNENs) compared with gastrointestinal NENs (5.8 months vs 1.8 months; p = .04). The overall response rate was higher in the first-line setting (51% vs 29%; p = .02) and in panNEN (41% vs 23%; p = .04). CONCLUSION: This is the largest TEM treatment series in G3 NEN, involving collaboration of several major North American NEN centers as a partnership. Thirty-six percent of patients showed some degree of radiographic response, and tre
- Published
- 2021